Aspen Pharmacare
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion (US$2.36 billion). In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.
| Company type | Public (JSE: APN) JSE Limited |
|---|---|
| Industry | Health care, pharmaceutical industry |
| Predecessor | Lennon Ltd |
| Founded | 1850, public 1997, Durban, South Africa |
| Headquarters | La Lucia Ridge, uMhlanga, KwaZulu-Natal , South Africa |
Key people | Stephen Saad (Group CE) |
| Products | Specialty branded pharmaceuticals including steriles, injectables, oral solid dose, liquids, semi-solids, biologicals, active pharmaceutical ingredients |
| Revenue | R 40,709,000,000 (FY 2023) |
Net income | R 16,811,000,000 (FY 2023) |
| Total assets | R 134,284,000,000 (FY 2023) |
| Total equity | R 86,236,000,000 (FY 2023) |
| Owner | JSE listed |
Number of employees | 9,100 |
| Website | www |